Publications by authors named "Maryam I Khan"
Article Synopsis
- Bone modifying agents (BMAs), like bisphosphonates and denosumab, are crucial for managing bone loss in early breast cancer and non-metastatic prostate cancer following endocrine therapy.
- Timely and effective use of BMAs can help minimize cancer treatment-induced bone loss (CTIBL), but optimal treatment strategies, such as dosing and monitoring, remain unclear for these populations.
- This review emphasizes the importance of tools like FRAX for assessing fracture risk and explores sequential therapy options, suggesting that certain patients may benefit from initiating BMAs earlier than typically recommended.
Electrolyte Disturbances in Critically Ill Cancer Patients: An Endocrine Perspective.
J Intensive Care Med
March 2018
Electrolyte disturbances are frequently encountered in critically ill oncology patients. Hyponatremia and hypernatremia as well as hypocalcemia and hypercalcemia are among the most commonly encountered electrolyte abnormalities. In the intensive care unit, management of critical electrolyte disturbances is focused on initial evaluation and immediate treatment plan to prevent severe complications.
View Article and Find Full Text PDFMolecular markers in thyroid cytology: diagnostic and prognostic implications.
Expert Rev Endocrinol Metab
September 2013
The discovery of thyroid nodules in the general population has risen markedly with the greater use of ultrasound resulting in increasing use of ultrasound-guided fine needle aspiration (FNA) biopsy. Although FNA can identify the majority of nodules as either benign or malignant, one-third of aspirates demonstrate indeterminate cytologic characteristics. Though most of these nodules will be pathologically benign, thyroid surgery has usually been needed to make an accurate diagnosis, and the extent of surgery needed (lobectomy versus total thyroidectomy) is difficult to predict in advance.
View Article and Find Full Text PDFObjective: To determine whether a random postoperative day-3 cortisol value of 10 μg/dL or greater is predictive of adrenal sufficiency 3 to 10 weeks after transsphenoidal surgery (TSS) and during long-term clinical follow-up.
Methods: We retrospectively reviewed the case records of patients who underwent TSS at our institution between 1991 and 2008. Inclusion criteria were as follows: random cortisol measured on the morning of postoperative day 3, adrenal dynamic testing performed 3 to 10 weeks after TSS, and clinical assessment of the hypothalamic-pituitary-adrenal (HPA) axis at least 6 months after TSS.
Objective: To provide a clinical update on the management of hypoparathyroidism with focus on postsurgical hypoparathyroidism.
Methods: Using PubMed, English-language literature was searched related to management of hypoparathyroidism after thyroid and parathyroid surgery. We discuss the incidence, pathophysiology, differential diagnosis, early diagnosis, and treatment of transient and permanent hypoparathyroidism.